Online Only Articles

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Dana-Farber Cancer Institute, Boston, MA, USA
Horizon Oncology Center, Lafayette, IN, USA
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA
Clearview Cancer Institute, Huntsville, AL, USA
Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA
Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA
University of Arizona Cancer Center, Tucson, AZ, USA
Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA
University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, TX, USA
The West Clinic, University of Tennessee Health Sciences Center, ACORN Research, LLC, Memphis, TN, USA
Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA
Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Berkeley Heights, NJ, USA
Celgene Corporation, Berkeley Heights, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA
Vol. 101 No. 7 (2016): July, 2016 https://doi.org/10.3324/haematol.2015.140806